Prenatal and Maternal Diagnostic Market Worth Over $10.5 billion to 2020

“Global Prenatal & Maternal Diagnostic Market To 2020”
The Global Prenatal & Maternal Diagnostic Market To 2020 report indicates that the launch of noninvasive prenatal screening tests (NIPTs) in 2011 dramatically altered the market dynamic, and this sub-section of the market will see an 18% CAGR to 2021.

A newly published analysis Global Prenatal & Maternal Diagnostic Market To 2020 indicates that by 2021, the global prenatal, maternal and newborn screening diagnostic test market will be worth over $10.5 billion, up from $8 billion today. This market is subdivided into ultrasound, fetal MRI, maternal serum and noninvasive prenatal screening technologies and will see a five year compound annual growth rate of 4.1%. The new report, entitled GLOBAL PRENATAL AND MATERNAL DIAGNOSTIC MARKET ANALYSIS indicates that the launch of noninvasive prenatal screening tests (NIPTs) in 2011 dramatically altered the market dynamic, and this sub-section of the market will see an 18% CAGR to 2021.  This is at the expense of more invasive techniques as chorionic villus sampling (CVS) or amniocentesis.

Global Prenatal & Maternal Diagnostic Market To 2020 report spreads across 359 pages strengthened with over 260 figures and tables is available at:

Since the 1960s, technologies for testing fetuses for conditions including trisomies have been continually advancing. The initial nongenetic testing such as ultrasound and serum screening for protein level markers, have developed remarkably throughout the years. Yet, these conventional tests are limited in sensitivity and specificity. Parallel to the development of these conventional technologies, two invasive techniques called amniocentesis and chorionic villus sampling (CVS) were introduced in 1980s to offer near 100% detection rates for trisomies. Yet, the chances of injury to the fetus and the consequence of miscarriages deterred both patients and obstetricians from using these techniques and to this date the techniques are used in high-risk pregnancies for the confirmation of positive results from screening tests.

When human genome sequencing was successfully accomplished, experts in the healthcare industry expected that DNA sequencing would mainly focus on genetic diseases in adults. Instead, the impact of sequencing technology has been primarily on prenatal, newborn and preimplantation genetic diagnosis (PGD) tests (prior to in vitro fertilization). In a short span of four years, the different types of maternal serum screening tests and fetal ultrasound tests are getting gradually replaced by the new technology of  non-invasive prenatal tests (NIPTs). In the past four years, hundreds and thousands of these new tests have been performed in screening cffDNA from maternal blood.

Purchase a Single User License Copy of “Global Prenatal & Maternal Diagnostic Market To 2020” Report at for US $3800.

The objective of this report is to provide an overview of the various technologies being employed for detecting genetic diseases in embryos, fetuses and newborns. The various chapters describe common pregnancy disorders, numerical chromosome disorders and structural chromosome disorders, single gene disorders inherited by fetuses, newborns and embryos.

The global prenatal and maternal diagnostic test market is assessed with respect to:

  • Fetal Ultrasound
  • Prenatal MRI Screening
  • Maternal Serum Screening Tests
  • Noninvasive Prenatal Tests (NIPTs) using cffDNA
  • NIPTs by Product
  • Prenatal Diagnostic Invasive Tests
  • Newborn Screening for Genetic Diseases
  • Newborn Screening Market by Technology
  • Preimplantation Screening/Diagnosis (PGS/PGD)

SWOT and merger/acquisition analysis is also performed as is a comprehensive documentation of the legislation pertaining to newborn screening by geography and how clinical programs are implemented in developed and developing markets.

Emerging trends in associated markets are also analysed in order to give the reader a comprehensive overview of how prenatal and maternal diagnostic testing is affected by the following industries:

  • Molecular Diagnostics Market
  • Liquid Biopsy Market
  • Personalized Medicine Diagnostics Market
  • In vitro Diagnostics (IVD) Market

Companies Mentioned:
23andMe Inc., Abbott Laboratories, Abbott Molecular Inc., Abcam plc, AB Sciex LLC, AdaltisS.r.l, Adaptive Biotechnologies Corp., Affymetrix Inc., Agena Biosciences Inc., Agilent Technologies Inc., Ambry Genetics Corp., Analogic Corp., Ariosa Diagnostics Inc., Ansh Labs, Appistry Inc., ARUP Laboratories, AssureRx Health Inc., Asuragen Inc., Athena Diagnostics Inc., AutoGenomics Inc., Base4 Innovation Ltd., Beckman Coulter Inc., Berry Genomics Co., Ltd., Bina Technologies Inc., Bio-Rad (Israel) Laboratories Inc., BGI, Blueprint Genetics Oy, Boreal Genomics Inc., Cambridge Epigenetix Ltd., Claris Lifesciences, CeGaT GmbH, Centogene AG, Chromosystems Instruments & Chemicals GmbH, Chronix Biomedical Inc., Claritas Genomics Inc., CLC bio A/S, Combimatrix Corp., Contec Medical Systems Co., Ltd., Coriell Life Sciences Inc., Correlagen Diagnostics Inc., Counsyl Inc., Courtagen Life Sciences Inc., Creative Diagnostics, Cynvenio Biosystems Inc., Diagnostic Automation/Cortex Diagnostics Inc., Demeditec Diagnostics GmbH, DRG International Inc., DNA Electronics Ltd., DNA Link Inc., DNAnexus Inc., Eagle Biosciences Inc., Eagle Genomics Ltd., Enzymatics Inc., Esoate SpA, Eurofins MWG Operon Inc., Exiqon A/S, Fakuda Denshi Co, Ltd., GATC Biotech AG, GE Healthcare Ltd., GenapSys Inc., Gene by Gene Ltd., Genection Inc., GeneDx Inc., GenePeeks Inc., Genesis Genetics, Genetadi Biotech S.L., Genoma Group Srl, Genomed AG, GenPath Diagnostics, Genway Biotech Inc., Good Start Genetics Inc., Hitachi Medical Systems America Inc., Hologic Inc., Illumina Inc., INEX Innovations Exchange Pte., Ltd., Invitae Corp., Laboratory Corporation of America Inc., Monobind Inc., Multiplicom NV, Myriad Genetics, Natera Inc., Natus Medical Inc., NewGene Ltd., NIPD Genetics Ltd., Oxford Gene Technology, Parabase Genomics Inc., Pathway Genomics Corp., PerkinElmer, Premaitha Health PLC, Progenity Inc., Qiagen N.V., Quest Diagnostics Inc., Ravgen Inc., Recombine Inc., Reproductive Genetics Institute Inc., Reprogenetics Laboratories, Sebia Inc., Sequenom Inc., SeraCare Life Sciences Inc., Siemens Healthcare, Sophia Genetics SA, SpOtOn Clinical Diagnostics Ltd., Stra Biotech GmbH, Sygnis AG, SynapDx Corp., Thermo Fisher Scientific Inc., Transgenomic Inc., Trivitron Healthcare Private Ltd., Trovagene Inc., Tute Genomics Inc., Warp Drive Bio LLC, ZS Genetics Inc. and Zymo Research Corporation.

Explore other reports by Kelly Scientific at:

About US: is an online market research reports library of 500,000+ reports and in-depth studies of 5000+ micro markets. offers research studies on agriculture, energy and power, automotive, Semiconductor and Electronics, Manufacturing & Construction, chemicals, environment, medical devices, healthcare, food and beverages, water and much more.

Media Contact
Company Name:
Contact Person: Ritesh Tiwari
Phone: +1 888 391 5441
Address:UNIT No 802, Tower No. 7, SEZ, Magarpatta city, Hadapsar
City: Pune
State: Maharashtra
Country: India